UpcomingPDUFA target action date

Zoryve (roflumilast) cream 0.05%

Arcutis Biotherapeutics (ARQT)

Marketer take

Extending down to infants as young as 3 months would put a nonsteroidal brand in pediatricians' and pediatric dermatologists' offices, where parent-facing steroid-sparing messaging matters.

Sponsor company
Arcutis Biotherapeutics (ARQT)
Indication
Atopic dermatitis in infants down to 3 months (sNDA)
Therapeutic area
Dermatology
Event
PDUFA target action date
Date
Feb 23, 2027
Status
Upcoming
Source
company press release
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move